Afridi Waqar Ahmed, Picos Samandra Hernandez, Bark Juliana Muller, Stamoudis Danyelle Assis Ferreira, Vasani Sarju, Irwin Darryl, Fielding David, Punyadeera Chamindie
Saliva and Liquid Biopsy Translational Laboratory, Institute for Biomedicine and Glycomics (IBG), Griffith University, Brisbane, 4111, Australia.
Virtual University of Pakistan, Islamabad, 44000, Pakistan.
Cancer Metastasis Rev. 2025 Jan 31;44(1):29. doi: 10.1007/s10555-025-10247-5.
CT chest scans are commonly performed worldwide, either in routine clinical practice for a wide range of indications or as part of lung cancer screening programs. Many of these scans detect lung nodules, which are small, rounded opacities measuring 8-30 mm. While the concern about nodules is that they may represent early lung cancer, in screening programs, only 1% of such nodules turn out to be cancer. This leads to a series of complex decisions and, at times, unnecessary biopsies for nodules that are ultimately determined to be benign. Additionally, patients may be anxious about the status of detected lung nodules. The high rate of false positive lung nodule detections has driven advancements in biomarker-based research aimed at triaging lung nodules (benign versus malignant) to identify truly malignant nodules better. Biomarkers found in biofluids and breath hold promise owing to their minimally invasive sampling methods, ease of use, and cost-effectiveness. Although several biomarkers have demonstrated clinical utility, their sensitivity and specificity are still relatively low. Combining multiple biomarkers could enhance the characterisation of small pulmonary nodules by addressing the limitations of individual biomarkers. This approach may help reduce unnecessary invasive procedures and accelerate diagnosis in the future. This review offers a thorough overview of emerging minimally invasive biomarkers for triaging lung nodules, emphasising key challenges and proposing potential solutions for biomarker-based nodule differentiation. It focuses on diagnosis rather than screening, analysing research published primarily in the past five years with some exceptions. The incorporation of biomarkers into clinical practice will facilitate the early detection of malignant nodules, leading to timely interventions and improved outcomes. Further efforts are needed to increase the cost-effectiveness and practicality of many of these applications in clinical settings. However, the range of technologies is advancing rapidly, and they may soon be implemented in clinics in the near future.
胸部CT扫描在全球范围内广泛应用,既用于各种适应症的常规临床实践,也作为肺癌筛查项目的一部分。许多此类扫描会检测到肺结节,即直径为8至30毫米的小圆形不透明区。虽然对结节的担忧在于它们可能代表早期肺癌,但在筛查项目中,此类结节中只有1%最终被证实为癌症。这导致了一系列复杂的决策,有时还会对最终被确定为良性的结节进行不必要的活检。此外,患者可能会对检测到的肺结节状况感到焦虑。肺结节检测的高假阳性率推动了基于生物标志物的研究进展,旨在对肺结节(良性与恶性)进行分类,以更好地识别真正的恶性结节。在生物流体和呼吸中发现的生物标志物因其微创采样方法、易用性和成本效益而具有前景。尽管几种生物标志物已显示出临床实用性,但其敏感性和特异性仍然相对较低。结合多种生物标志物可以通过解决单个生物标志物的局限性来增强对小肺结节的特征描述。这种方法可能有助于减少未来不必要的侵入性程序并加速诊断。本综述全面概述了用于肺结节分类的新兴微创生物标志物,强调了关键挑战并提出了基于生物标志物的结节鉴别潜在解决方案。它侧重于诊断而非筛查,主要分析过去五年发表的研究,但有一些例外。将生物标志物纳入临床实践将有助于早期发现恶性结节,从而实现及时干预并改善预后。需要进一步努力提高许多此类应用在临床环境中的成本效益和实用性。然而,技术范围正在迅速发展,它们可能很快在不久的将来在临床中得到应用。